Gabapentin Tablet
Product Images NDC 68788-8488

7 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8488). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr (Equation)

Clcr (Equation)
An illustration showing the formula for Creatinine Clearance (CLCr), which calculates kidney function based on age, weight, serum creatinine, and a gender adjustment factor for female patients (0.85 multiplier). The formula is presented mathematically with variables for age in years, weight in kilograms, and serum creatinine in mg/dL.*
FDA Label Image

Struc (Struct)

Struc (Struct)
Chemical structure of gabapentin showing a cyclohexane ring attached to aminomethyl and acetic acid groups.*
FDA Label Image

Figure-1 (Figure1)

Figure-1 (Figure1)
A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' compares mean pain scores over 8 weeks between Placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks from Baseline to 8; the y-axis shows mean pain score from 0 to 10. The Gabapentin group demonstrates a decreasing pain score trend, while the Placebo group remains relatively stable. The graph is divided into two 4-week periods labeled 'Dose Titration' and 'Fixed Dose.'*
FDA Label Image

Figure-2 (Figure2)

Figure-2 (Figure2)
Line chart titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2', showing mean pain scores over 7 weeks. The x-axis is labeled 'Weeks' and y-axis labeled 'Mean Pain Score' from 0 to 10. It compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day over a 3-week dose titration period followed by a 4-week fixed dose period.*
FDA Label Image

Figure-3 (Figure3)

Figure-3 (Figure3)
A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatment groups. Two studies are shown: Study 1 with 12% responders for placebo and 29% for GBP 3600 mg; Study 2 with 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated for gabapentin groups.*
FDA Label Image

Figure-4 (Figure4)

Figure-4 (Figure4)
A scatter plot showing responder rate differences from placebo by daily dose (600 mg to 1800 mg) for gabapentin in adjunctive therapy studies of patients aged 12 years or older with partial seizures. Data points distinguish three studies labeled a, b, and c, with responder rates ranging from about 8% to 18%.*
FDA Label Image

Gabapentin Tab 600mg Cv (800 mg 500s)

Gabapentin Tab 600mg Cv (800 mg 500s)
Label for Gabapentin Tab 600mg (CV) tablets by Preferred Pharmaceuticals, Inc. The label states each tablet contains 600mg gabapentin, generic for Neurontin. It includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc.), barcodes, and directions for use in English and Spanish. Several fields for quantity, lot, batch, and NDC numbers are present but not filled in.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.